Many people in Australia, including psychiatrists, were when earlier this year the medicines regulator MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.
Authors
Nigel Strauss
Psychiatrist and Clinical Associate at The Centre of Mental Health, Swinburne University of Technology
Colleen Loo
Professor of Psychiatry, UNSW & Black Dog Institute, UNSW Sydney
David Jonathan Castle
Chair of Psychiatry, The University of Melbourne
Steve Kisely
Professor, School of Medicine, The University of Queensland
This means that under certain circumstances from July 1, will be able to prescribe MDMA to treat post-traumatic stress disorder and psilocybin to treat depression that has not responded to other treatments. Patients must also undergo psychotherapy (talking therapy).
It all sounds very certain but it’s not really.
Beware the hype
The Therapeutic Goods Administration decision has left a lot of about how the new scheme will be implemented and operated, both effectively and safely.
There are a small number of countries where psychedelic-assisted therapies are used outside clinical trials – in a very limited manner. However, this is the first time a national government has altered the way these substances are formally classified.
So the world is watching closely how “psychedelic-assisted therapy”, as it’s officially called, is rolled out in Australia.
It’s a hot topic, with much . But for researchers, there are concerns the hype is getting way ahead of the research.
The first steps
The Royal Australian and New Zealand College of Psychiatrists this week to their members about how this would work in practice.
As researchers in this field, we helped develop these guidelines. They cover topics such as patients’ suitability for this therapy, and how to administer and monitor it.
The guidelines also stress the importance of patient safety and appropriate training for prescribers, and advocates for continued research.
What does this mean for patients?
This has several implications for potential patients:
their existing psychiatrist may not be authorised to prescribe these psychedelics. So patients will have to ask their psychiatrist or GP for a referral to one who is
the psychiatrist authorised to prescribe these psychedelics will need to assess whether the therapy is suitable for each individual patient. This involves a detailed and comprehensive assessment. If the treatment is suitable, several sessions of further assessment and therapy are required before the actual dosing session
patients will be informed of what to expect before, during and after treatment, and need to give consent to proceed. We also recommend psychiatrists tell patients this therapy is not guaranteed to work, and provide patients with a clear account of the risks and possible negative side effects of psychedelic medications.
Expectations are high, but clear evidence is lacking
Despite a growing , psychedelic-assisted therapies are in their infancy.
In a time when demand for mental health services , exaggerated promises about the effectiveness of these drugs, before the research results are in, has many researchers worried. Patient expectations remain high but good clear evidence is still lacking.
Australian research is just getting under way and so far most psychedelic research has been done overseas. Yes, early findings have been , but numbers are small, long-term follow-ups sparse, and potential risks and dangers still need to be explored.
Destigmatising these drugs has allowed us to begin our research, but sensationalising their effectiveness has the potential to disappoint and even harm patients because we really don’t know enough about how they work and who is suitable for this treatment.
Psychedelic-assisted therapy is no miracle cure. Espousing the benefits without a thorough examination of the risks and limitations is not only a misrepresentation of the science, it is arguably unethical.
Very few psychiatrists have had much experience in this fascinating but challenging field. We still have a lot to learn about the use of psychedelic medicines to treat psychiatric illness.
Undue haste in translating psychedelic-assisted therapy conducted in clinical trials to community clinics could affect how well these treatments work and their safety. Outside clinical trials, patients will also need to shoulder the of this therapy, raising equity issues.
There’s potential for harm
Psychedelic-assisted therapy is not simply “doing shrooms with your shrink”.
There is potential for psychedelic substances to cause fear, panic or cause psychological damage if given to susceptible and vulnerable people who have been inadequately screened or assessed.
Paranoia, traumatisation, worsening depression, and even suicidal behaviour, among other , in some cases.
So we need ongoing monitoring of outcomes, including adverse events.
We also know psychedelic substances render patients particularly vulnerable. Boundary issues and safeguards are vital considerations for patient safety, particularly when patients are under the influence of the psychedelic drug. For instance, it is important to discuss and agree with patients beforehand about the nature and timing of any touch during treatment sessions, so any touch is appropriate and done with full informed consent.
An exciting prospect
Despite the potential harms, we remain excited at the prospect of psychedelic-assisted therapy becoming an established treatment to help a select group of patients.
But we want to do this in a safe, controlled and sustainable manner.
If this article has raised issues for you, or if you’re concerned about someone you know, call Lifeline on 13 11 14.
Nigel Strauss is a psychiatrist and senior consultant with St Vincent’s Hospital Melbourne, an investigator on several psychedelic clinical trials, is on the scientific advisory board of the European Mind Foundation, and is the medical director of the Millswyn Clinic in Melbourne, a private psychiatric clinic. He has made his own philanthropic donation to Monash University for a trial of MDMA assisted psychotherapy for PTSD. The trials he’s involved in have not personally received any funding.
Colleen Loo receives research grant funding from the Australian NHMRC and MRFF.
David Jonathan Castle has received grant monies for research from Servier, Boehringer Ingelheim; travel support and honoraria for talks and consultancy from Servier, Seqirus, Lundbeck, Mindcafe, Psychscene, Inside Practice. He is a founder of the Optimal Health Program (OHP) and holds 50% of the IP for OHP; and is part owner (5%) of Clarity Healthcare. He is an unpaid Chair of an Advisory Board of Psychae, an Australian not-for-profit institute specialising in psychedelic medicines research. He is a member of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Assisted Therapy Working Group. He does not knowingly have stocks or shares in any pharmaceutical company.
Steve Kisely was the first author of the report commissioned by the Therapeutic Goods Administration on the possible clinical benefits of MDMA and psilocybin.
